Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via cyclic GMP

International Journal of Gastrointestinal Cancer

Volumn 36, Issue 2, 2005, Pages 77-88

  Gower Jr , William R ^a   Vesely, Brian A ^a   Alli, Abdel A ^a   Vesely, David L ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Cyclic GMP; DNA synthesis; Natriuretic peptides; Peptide hormones; Preclinical; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DNA; KALIURETIC PEPTIDE; LONG ACTING DRUG; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE A RECEPTOR; NATRIURETIC PEPTIDE C RECEPTOR; NATRIURETIC PEPTIDE TYPE C; PEPTIDE HORMONE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CELL COUNT; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS ADENOCARCINOMA; PEPTIDE ANALYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

EID: 33745697992     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:36:2:77     Document Type: Article

References (24)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Bresalier RS. Malignant neoplasms of the large intestine, in Gastrointestinal and Liver Disease: Pathophysiology/ Diagnosis/Management. 7th Ed., vol. 2. (Feldman M, Friedman LS, Sleisenger MH, eds.) Saunders, Philadelphia, PA, 2002; pp. 2215-2261.
3. Vesely BA, McAfee Q, Gower WR Jr, Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003;33:998-1005.
4. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J, Gower WR Jr. Novel therapeutic approach forcancerusing four cardiovascular hormones. Eur J Clin Invest 2004;34:674-682.
5. Vesely BA, Song S, Sanchez-Ramos J, et al. Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 2005;35:60-69.
6. Vesely DL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-159.
7. Vesely DL, Norris JS, Walters JM, Jespersen RR, Baeyens DA. Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Communv 1987;148:1540-1548.
8. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990;258:F1401-1408.
9. 2. J Clin Invest 1992;89:1411-1417.
10. Dietz JR, Scott DY, Landon CS, Nazian SJ. Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol 2001;280:R1510-R1517.
11. Vesely DL, Douglass MA, Dietz JR, et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 1994;90:1129-1140.
12. Vesely DL, Douglass MA, Dietz JR, et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994;78:1128-1134.
13. Vesely DL, Dietz JR, Parks JR, et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998;98:323-329.
14. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol 2003;285:F167-F177.
15. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-449.
16. Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scan J Clin Lab Invest 1998;58:205-216.
17. Franz M, Woloszczuk W, Horl WH. Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 2001;59:1928-1934.
18. Dexter DL, Barbosa JA, Calabresi P. N, N-Dimethyl-foramide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res 1979;39:1020-1025.
19. Vesely DL. Signal transduction: Activation of the guanylate cyclase-cyclic guanosine-3′5′ monophosphate system by hormones and free radicals. Am J Med Sci 1997;314:311-323.
20. Vesely BA, Fitz SR, Gower WR Jr, Vesely DL. Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 2006;232:226-231.
21. Vesely BA, Song S, Sanchez-Ramos J, et al. Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 2005; 35:388-398.
22. Saba SR, Garces AH, Clark LC, Soto J, Gower WR, Jr, Vesely DL. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long acting natriuretic peptide and kaliuretic peptide in human pancreatic adenocarcinomas. J Histochem Cytochem 2005; 53:989-995.
23. Mohapatra SS, Lockey RF, Vesely DL, Gower WR, Jr. Natriuretic peptides and genesis of asthma: An emerging paradigm? J Allergy Clinical Immuol 2004; 114:520-526.
24. Suga SI, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992; 130: 229-239.